Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

PharmaCyte Biotech, Inc. PMCB

Set alert

Price alert · PMCB

All alert types
0.31 USD +0.01 +2.71%

At close · Nov 2

0.32 +0.01 +2.19%

After hours · Nov 2, 4:00 PM ET

Bid
0.29 × 2
Ask
0.32 × 2
0.31 Day range 0.32
0.3021 52-week range 1.51
YTD
-57.14%
1 year
-66.63%
Open
0.31
Prev close
0.3021
Mkt cap
3.33M
Vol
40.84K
Avg vol
185.15K
EPS
-2.31
P/E
0.00
Div yield
0.00%
More statistics
Low
0.31
High
0.32
Forward P/E
-4.21
Beta
-0.20
Short ratio
1.09
Inst. own
13.16%
Dividend
0.00
Ex-div date
50-d avg
1.73
200-d avg
1.94
1y target
0.00

2Y chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Dec 13, 2024Earnings: -0.29; estimate 0; surprise —%
Signals (109)
NameDateAgo
MACD: Sell SignalOct 30, 20263 days ago
RSI: OversoldOct 30, 20263 days ago
MACD: Buy SignalOct 23, 20261 week ago
MACD: Sell SignalOct 13, 20262 weeks ago
MACD: Buy SignalSep 21, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
RSI: OversoldSep 9, 20261 month ago
MACD: Buy SignalSep 8, 20261 month ago
MACD: Sell SignalSep 2, 20262 months ago
RSI: OversoldSep 1, 20262 months ago
MACD: Buy SignalAug 21, 20262 months ago
MACD: Sell SignalAug 20, 20262 months ago
RSI: OversoldAug 20, 20262 months ago
MACD: Buy SignalAug 19, 20262 months ago
MACD: Sell SignalAug 18, 20262 months ago
RSI: OversoldAug 18, 20262 months ago
MACD: Buy SignalAug 13, 20262 months ago
MACD: Sell SignalAug 12, 20262 months ago
MACD: Buy SignalAug 5, 20262 months ago
SMA: BearishJul 1, 20264 months ago

Newest 20 of 109.

Key statistics

Financials
Market cap
11.15M
Enterprise value
-14.09M
Trailing P/E
1.82
Forward P/E
-4.21
PEG ratio
0.00
Price / sales
0.00
Price / book
0.47
EPS (TTM)
0.88
Beta
-0.20
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
3.13M
Total cash
32.64M
Total debt
0
Return on equity
47.88%
Shares outstanding
6.97M
Short % of float
1.18%
50-day average
1.73
200-day average
1.94

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PMCB Revenue — quarterly 0
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
PMCB Net income — quarterly -5.08M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
PMCB EPS — quarterly -0.54
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

PMCB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 13, 2024Oct 1, 20240.00-0.29——
Sep 16, 2024Jul 1, 20240.000.14——
Aug 13, 2024Apr 1, 20240.00-0.85——
Mar 18, 2024Jan 1, 20240.00-0.65——
Dec 15, 2023Oct 1, 20230.00-0.64——
Sep 18, 2023Jul 1, 20230.00-0.28——

Upgrades / downgrades

PMCB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2021HC Wainwright & Co.init—Neutral

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
pharmacyte.com

News

All news

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on PMCB — it syncs with the Stock Master app.

Institution ownership

PMCB institution ownership
Holder% heldSharesValueReported
Geode Capital Management, LLC0.01%168,200269.12KSep 29, 2024
Vanguard Group Inc0.01%192,387307.82KSep 29, 2024
K2 Principal Fund, L.P.0.01%209,266334.82KSep 29, 2024
Equitec Proprietary Markets LLC0.00%82,727132.36KSep 29, 2024
Dimensional Fund Advisors LP0.00%27,60144.16KSep 29, 2024
Renaissance Technologies, LLC0.00%49,70079.52KSep 29, 2024

Fund ownership

PMCB fund ownership
Holder% heldSharesValueReported
Schwab Capital Trust-Total Stock Market Index Fund0.00%5,9479.52KJul 30, 2024
DFA U.S. Targeted Value Portfolio0.00%2,0093.21KJul 30, 2024
Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF0.00%11,50618.41KJul 30, 2024
Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF0.00%8,70713.93KJul 30, 2024
Vanguard Total Stock Market Index Fund0.00%117,468187.95KSep 29, 2024
Vanguard Extended Market Index Fund0.00%74,919119.87KSep 29, 2024

Splits

PMCB stock splits
DateRatio
Jul 12, 20211:1492